Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01225913 · ClinicalTrials.gov registry record · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
A Phase 4 study of Asthma, sponsored by Gelb, Arthur F., M.D..
- Recruiting
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT01225913: Recruiting Phase 4 study of Asthma, sponsored by Gelb, Arthur F., M.D..
NCT01225913 is a Phase 4 study of Asthma that is actively recruiting participants, run by Gelb, Arthur F., M.D.. The registered enrollment target is 50 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01225913, a Phase 4 study of Asthma, is actively recruiting participants, sponsored by Gelb, Arthur F., M.D..
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the site and mechanisms responsible for expiratory airflow limitation in chronic, treated, non-smoking, stable asthmatics with moderate to severe persistent expiratory airflow obstruction. Treatment will include inhaled corticosteroids and long acting beta2agonists. The investigators are interested in determining whether the large and/or small airways are the predominant site of airflow limitation. The investigators are also interested in determining whether intrinsic small airways obstruction and/or loss of lung elastic recoil is responsible for expiratory airflow limitation. The investigators are also interested to evaluate the role of varying doses of inhaled corticosteroids to suppress large and small airway inflammation using exhaled nitric oxide as surrogate markers of inflammation. For comparison purposes, spirometry and measurements of exhaled nitric oxide will also be obtained if possible during a naturally occurring exacerbation of asthma.
Primary Outcome
evaluate the role of inhaled corticosteroid on exhaled nitric oxide production in large airways and peripheral small airways/alveoli
Conditions Studied
Interventions
- DRUG fluticasone/salmeterol in all asthmatics
- DRUG budesonide/formoterol or fluticasone/salmeterol in all asthmatics
Study Locations (1)
California
- Arthur F Gelb Medical Corporation - Lakewood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2007-10 |
| Est. Completion | 2027-06 |
| Phase | Phase 4 |
What NCT01225913 shows while recruiting
NCT01225913 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which fluticasone/salmeterol in all asthmatics is the first listed.
NCT01225913 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01225913 about?
NCT01225913 is a clinical study titled "Mechanism(s) of Airflow Limitation During Exacerbation of Asthma". The purpose of this study is to evaluate the site and mechanisms responsible for expiratory airflow limitation in chronic, treated, non-smoking, stable asthmatics with moderate to severe persistent expiratory airflow obstruction. Treatment will include inhaled corticosteroids and long acting beta2ag...
What is the current status of trial NCT01225913?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2007-10. Estimated completion is 2027-06.
What conditions does trial NCT01225913 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT01225913?
The interventions under investigation include: fluticasone/salmeterol in all asthmatics (DRUG), budesonide/formoterol or fluticasone/salmeterol in all asthmatics (DRUG).
Who is sponsoring clinical trial NCT01225913?
This trial is sponsored by Gelb, Arthur F., M.D., which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01225913 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01225913's enrollment target sits among peer trials
50 263rd of 374 higher than 106 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
RECRUITING · Phase 4
-
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 4
-
Viral Infection in Asthma (VIA) Study
RECRUITING · Phase 4
-
The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)
RECRUITING · Phase 4
-
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
RECRUITING · Phase 4
-
Individualizing Treatment for Asthma in Primary Care (Full Study)
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01746836 · 50 participants · Phase 2
Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia